Abstract:Copper is an element required for cell proliferation and angiogenesis. Human prostate cancer xenografts with increased Cu-64 radioactivity were visualized previously by PET using (CuCl2)-Cu-64 as a radiotracer ((CuCl2)-Cu-64 PET). This study aimed to determine whether the increased tumor 64Cu radioactivity was due to increased cellular uptake of 64Cu mediated by human copper transporter 1 (hCtr1) or simply due to nonspecific binding of ionic 64CuCl2 to tumor tissue. In addition, the functional role of hCtr1 in proliferation of prostate cancer cells and tumor growth was also assessed. Methods: A lentiviral vector encoding short-hairpin RNA specific for hCtr1 (Lenti-hCtr1-shRNA) was constructed for RNA interference-mediated knockdown of hCtr1 expression in prostate cancer cells. The degree of hCtr1 knockdown was determined by Western blot, and the effect of hCtr1 knockdown on copper uptake and proliferation were examined in vitro by cellular 64Cu uptake and cell proliferation assays. The effects of hCtr1 knockdown on tumor uptake of 64Cu were determined by PET quantification and tissue radioactivity assay. The effects of hCtr1 knockdown on tumor growth were assessed by PET/CT and tumor size measurement with a caliper. Results: RNA interference-mediated knockdown of hCtr1 was associated with the reduced cellular uptake of 64Cu and the suppression of prostate cancer cell proliferation in vitro. At 24 h after intravenous injection of the tracer 64CuCl2, the 64Cu uptake by the tumors with knockdown of hCtr1 (4.02 +/- 0.31 percentage injected dose per gram [% ID/g] in Lenti-hCtr1-shRNA-PC-3 and 2.30 +/- 0.59 % ID/g in Lenti- hCtr1- shRNA- DU- 145) was significantly lower than the 64Cu uptake by the control tumors without knockdown of hCtr1 (7.21 +/- 1.48% ID/g in Lenti-SCR-shRNA-PC-3 and 5.57 +/- 1.20% ID/g in Lenti-SCR-shRNA-DU-145, P, 0.001) by PET quantification. Moreover, the volumes of prostate cancer xenograft tumors with knockdown of hCtr1 (179 +/- 111 mm(3) for Lenti-hCtr1-shRNAPC- 3 or 39 +/- 22 mm(3) for Lenti-hCtr1-shRNA-DU-145) were significantly smaller than those without knockdown of hCtr1 (536 +/- 191 mm(3) for Lenti-SCR-shRNA-PC-3 or 208 +/- 104 mm(3) for Lenti-SCR-shRNA-DU-145, P, 0.01). Conclusion: Overall, data indicated that hCtr1 is a promising theranostic target, which can be further developed for metabolic imaging of prostate cancer using (CuCl2)-Cu-64 PET/CT and personalized cancer therapy targeting copper metabolism.

Correlation of Expression of Human Copper Transporter 1 with Cisplatin Resistance in Ovarian Carcinoma

Effect of Lung Resistance-Related Protein on the Resistance to Cisplatin in Human Ovarian Cancer Cell Lines.

[Effects of Cisplatin on Telomerase Activity of Human Choroidal Melanoma Cells].

Reduced 64cu Uptake and Tumor Growth Inhibition by Knockdown of Human Copper Transporter 1 in Xenograft Mouse Model of Prostate Cancer.

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Cisplatin on the Effect of Aquaporin 5 Protein Expression of SKOV3 and Its Regulation

Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer

Effects of Platinum Compounds on Biological Behaviour and Expression of MDR1 in Gastric Cancer Cells

Effects of aquaporins on chemosensitivity to cisplatin in ovarian cancer cells

[Basic Research of the Adenovirus-mediated hCTR1 Transfection on the Treatment of Cisplatin Resistant Cervical Cancer]

Claudin-3 and Claudin-4 Regulate Sensitivity to Cisplatin by Controlling Expression of the Copper and Cisplatin Influx Transporter CTR1

Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy

How Progesterone Receptor Expression Impacts Platinum Sensitivity in Ovarian Clear Cell Carcinoma: Insights from Clinical and Experimental Perspectives

The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer

Mitochondrial Dynamics Mediated by DRP1 and MFN2 Contributes to Cisplatin Chemoresistance in Human Ovarian Cancer SKOV3 cells

Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity

The Telomerase Activity and Expression of Htert Gene Can Serve As Indicators in the Anti-Cancer Treatment of Human Ovarian Cancer.

Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.

Effect of Sirna-Induced Atg7 Gene Silencing on the Sensitivity of Ovarian Cancer SKOV3 Cells to Cisplatin.

Study on the relationship between expression levels of ERCC1 mRNA and sensitivity of tumor cells isolated from malignant effusions to cisplatin in vitro